RPRX Dec 2022 40.000 put
| Previous close | 5.0000 |
| Open | 5.0000 |
| Bid | 1.6000 |
| Ask | 6.5000 |
| Strike | 40.00 |
| Expiry date | 2022-12-16 |
| Day's range | 5.5000 - 5.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- GlobeNewswire
Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders
New capital deployment target of $10-12 billion over the next five yearsOutlook for 2020-2025 Adjusted Cash Receipts (1) (non-GAAP) CAGR raised to 11-14%Adjusted Cash Receipts (1) (non-GAAP) expected to grow 10% or more over this decade, positioning Royalty Pharma to be one of the fastest growing biopharma companiesDemand for capital to fund life sciences innovation to exceed $1 trillion in next decade NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host its ina
- GlobeNewswire
Royalty Pharma Reports First Quarter 2022 Results
Net cash provided by operating activities (GAAP) of $460 million; Adjusted Cash Receipts(1) (non-GAAP) of $605 million Announced transactions of up to $450 million in Q1 20222022 guidance reaffirmed: Adjusted Cash Receipts(1) expected to be $2,225 to $2,300 million NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial mea
- Simply Wall St.
With Royalty Pharma plc (NASDAQ:RPRX) It Looks Like You'll Get What You Pay For
Royalty Pharma plc's ( NASDAQ:RPRX ) price-to-earnings (or "P/E") ratio of 41.8x might make it look like a strong sell...
